Therion Biologics Contact UsSitemapHome
Company Overview Science Clinical Trials Patient Resources Press Room
Press Room

Corporate Backgrounder (PDF)

Home > Press Room

Pressroom

Company News

Therion Reports Results of Phase 3 PANVAC-VF Trial
Company Sale Plan Is Announced
June 29, 2006

Therion Reports Results of Phase 2 PROSTVAC�-VF Trial at ASCO Annual Meeting and Formalizes Plan for an NCI-Sponsored Phase 3 Study
Potential Survival Difference Identified in Phase 2 Study
June 3, 2006

Therion Biologics Announces Conclusion of PANVAC-VF Phase 3 Trial
-Presentations of Therion�s targeted immunotherapeutics to be presented at annual ASCO meeting in Atlanta-
June 1, 2006

Therion Completes Phase III Enrollment for PANVAC-VF Pancreatic Cancer Trial; BLA Planned for 2006
February 10, 2006

Therion Biologics Secures $50 Million to Complete Pivotal Clinical Development Program
Funding for Continued Commercialization Preparation
December 27, 2005

Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial of PROSTVAC�-VF in Androgen Independent Prostate Cancer
July 7, 2005

Therion Biologics Corporation Secures $30 Million in Private Equity Financing
- Appoints Kathryn Davis as Vice President, Clinical Affairs -
June 17, 2005

Therion Announces Oral Presentation of Data from Phase II PROSTVAC-VF Study in Patients with Androgen-Independent Prostate Cancer
- PROSTVAC-VF treatment associated with declines in PSA at 3 months and a clear partial tumor response for one patient at 8 months -
May 16, 2005

Therion Announces Presentation of Follow-up Clinical Data Regarding Its Novel Targeted Cancer Therapy PANVAC-VF at ASCO
- Data suggest PANVAC-VF treatment may result in prolonged overall survival for patients with advanced pancreatic cancer -
May 15, 2005

Therion Announces Oral Presentation of Clinical Data on Its Targeted Cancer Therapy PROSTVAC-VF at ASCO
- Therion�s prime/boost regimen results in favorable clinical response with stable PSA scores at 50 months -
May 14, 2005

Therion Announces Upcoming Oral and Poster Presentations at ASCO on Lead Programs in Prostate and Pancreatic Cancer
May 11, 2005

RESEARCHERS PUBLISH SUPPORTING SAFETY AND ANTI-TUMOR ACTIVITY OF THERION BIOLOGICS� CEA-TRICOM� THERAPEUTIC VACCINE IN JOURNAL OF CLINICAL ONCOLOGY
FOR IMMEDIATE RELEASE
December 22, 2004

THERION BIOLOGICS TO PRESENT AT MASS OPPORTUNITIES BIOTECHNOLOGY INVESTMENT CONFERENCE
Company to Provide Overview of Late-stage Clinical Programs in Pancreatic and Prostate Cancer
October 29, 2004

THERION BIOLOGICS TO PRESENT AT BIO EMERGING COMPANY INVESTOR FORUM
-CEO to Discuss Programs Recently Highlighted in FDA Consumer-
Press Release
October 11, 2004

THERION BIOLOGICS NAMED AMONG TOP 15 EMERGING BIOTECH COMPANIES OF 2004
Therion Biologics Represents the Future of Immunotherapy Treatments for Cancer
July 28, 2004

Therion Biologics Corporation Initiates Phase III Clinical Trial With
PANVAC-VF In Advanced Pancreatic Cancer
June 21, 2004

Researchers Present Results from Studies of Therion�s Therapeutic Cancer Vaccines in Patients with Pancreatic Cancer
-- Data presented today at ASCO (abstracts #2564 and #2513) form basis for company�s planned Phase III clinical study of PANVAC-VF --
June 7, 2004

Therion Biologics Corporation Receives FDA Agreement to Initiate Phase III Clinical Trial with PANVAC-VF in Advanced Pancreatic Cancer
May 24, 2004

Therion Biologics Obtains Rights to Biogen Idec LFA-3 Patents
December 15, 2003

Therion Begins Phase II Clinical Trial of PROSTVAC�-VF as Immunotherapy for Prostate Cancer
November 19, 2003

Massachusetts Governor Mitt Romney Today Commemorates Opening of Therion
September 10, 2003

Therion Biologics Corporation Secures $39 Million in Private Equity Financing to Advance Several Phase II Clinical Trials and Expand Manufacturing Capabilities
September 8, 2003

Scientists from the National Cancer Institute Demonstrate that Therion�s Fowlpox-Based Melanoma Vaccine Can Generate Immune Responses in Patients With Melanoma
-- Phase II clinical results reported in August issue of Clinical Cancer Research --
August 15, 2003

Therion Biologics Corporation Appoints Thomas J. Schuetz, M.D., Ph.D., as Chief Medical Officer
June 30, 2003

Georgetown Researchers Confirm Safety and Demonstrate First Evidence of Clinical Activity of Therion Biologics
-- Phase I data presented today at ASCO, Abstract #662, demonstrate enhanced immune response with addition of three co-stimulatory molecules to vaccine --
-- Dr. John Marshall of Georgetown University to highlight data at ASCO press briefing today at 2:30 pm --
June 1, 2003

Therion Biologics leases 8,400 square feet at American Twine Office Park in Cambridge
March 31, 2003

Therion Biologics Corporation Appoints Richard J. Meadows to Board of Directors
February 18, 2003

Therion Biologics and the National Institute of Allergy and Infectious Diseases, NIH, Initiate Human Clinical Trials of Preventive Smallpox Vaccine
-- Phase I Clinical Trial of TBC-MVA Smallpox Vaccine Begins --
December 19, 2002

Therion Biologics Licenses ICAM-1 from
September 17, 2002

Therion Biologics Corporation Strengthens Management Team
-- Appoints George A. Eldridge as Chief Financial Officer; Suman Patel, Ph.D. as Vice President of Quality; and Erin E. Quinn as Vice President of Human Resources --
September 9, 2002

Columbia/ECOG Researchers Stabilize PSA Levels and Clinical Progression in Prostate Cancer Patients Following Treatment with Therapeutic Vaccines
-- Phase II Data Presented at ASCO Illustrate Likely Clinical Benefit of Therion
May 19, 2002

Therion Biologics Adds to Board of Directors
-- Peter R. Wolfe, M.D., Partner and Director of Research at Pacific Oaks Medical Group, and Trudie Resch, Partner of CDP Sofinov --
April 3, 2002

Therion Names Mark Leuchtenberger, Former Vice President of Biogen International, as President and CEO
-- Dennis L. Panicali, Ph.D., Appointed to Newly Created Position of Chief Scientific Officer--
March 27, 2002

Therion Biologics and the Ludwig Institute Initiate Clinical Study of Cancer Vaccine in Europe
-- Begin Phase I Clinical Trial of Vaccine Based on ESO-1 Tumor-Associated Antigen --
January 2, 2002

Therion Biologics Strengthens Position in Cancer Immunotherapy with Acquisition of Key Patents from the U.S. Public Health Service
November 27, 2001

Therion Expands Clinical Capabilities with Appointment of Two Senior Executives
--Jeff Edelson, M.D. as Chief Medical Officer and Sr. Vice President, Clinical Development; Michael Wyand, D.V.M., Ph.D. as Sr. Vice President, Research and Development--
August 22, 2001

Georgetown Researchers Achieve Increased Cancer Patient Survival Following Treatment with Therapeutic Vaccines
-- New Data at ASCO Meeting Shows First Correlation Between Increased Immune Responses and Patient Survival with Therion vaccines --
May 14, 2001

IAVI and Therion Form Collaboration to Advance Preventative Vaccines for AIDS
-- Program Aimed at Fighting AIDS in Developing Countries --
March 20, 2001

Therion Biologics and National Cancer Institute Initiate Human Clinical Trials of Next-Generation Product for Colorectal Cancer
--Begins Phase I Clinical Trial of CEA-TRICOM Cancer Vaccine--
February 20, 2001

Therion Biologics and Aventis Pasteur Expand Cancer Vaccine Alliance
--Clinical Results Move Colorectal Cancer Products Forward--
October 26, 2000

Promising Therapeutic Vaccine for Prostate Cancer Enters Expanded Clinical Studies
--National Cancer Institute Sponsors Additional Phase II trials for Therion Biologics' PROSTVAC VF--
September 7, 2000

Therapeutic Prostate Cancer Vaccine Shows Promise in Early Clinical Study
-- Dana-Farber Cancer Institute, National Cancer Institute and Therion Biologics Report in Clinical Cancer Research Results of a Phase I Study of Therion's PROSTVAC vaccine --
May 11, 2000

Therion and National Cancer Institute Extend Collaborations
February 14, 2000

Therion Appoints Former Wyeth-Lederle Vaccines President, Ronald J. Saldarini, Ph.D., to Board of Directors
December 6, 1999

Therion Awarded AIDS Vaccine Manufacturing Contracts from NIH
--Three agreements provide over $1.5 million in funding for development of novel vaccines and research products--
November 29, 1999

Therion Appoints Richard Woodrich as Senior Vice President, Business Development
November 17, 1999

Therion Biologics and National Cancer Institute Initiate Phase II Trial of Novel Melanoma Vaccines
--Newest vaccines join Therion's cancer portfolio with additional prostate, colorectal and lung cancer products in efficacy studies--
October 18, 1999

Therion Completes $10.5 Million Financing to Accelerate Cancer Vaccine Development
-- Portfolio includes seven vaccines in Phase I and Phase II clinical trials --
June 28, 1999

Therion Obtains Rights to Novel Gene from Ludwig Institute for Cancer Vaccines
--Collaboration covers immunotherapy products based on ESO-1 tumor-associated antigen--
September 16, 1998

New Agreement to Find Cancer Vaccines
--Pasteur M�rieux Connaught (Rhone-Poulenc Group), Therion Biologics to Develop and Market Vaccines for Colorectal, Lung Cancers and Melanoma--
January 14, 1998

Francis P. Tally, M.D., Appointed to Therion Biologics Board of Directors
July 31, 1997

Therion Biologics Issued Broad U.S. Patents Covering Fundamental AIDS Vaccine Technology
July 14, 1997

Publications

Vaccine Company Doubles Its Money
BioVenture View
September 1, 2003
Cancer Vaccines: Training the Immune System to Fight Cancer
FDA Consumer
September 1, 2004
Phase I Study of Sequential Vaccinations With
Journal of Clinical Oncology
December 21, 2004